Avian Influenza Vaccine Research Articles

Antibodies elicited by Newcastle disease virus-vectored H7N9 avian influenza vaccine are functional in activating the complement system

H7N9 subtype avian influenza virus poses a great challenge for poultry industry. Newcastle disease virus (NDV)-vectored H7N9 avian influenza vaccines (NDVvecH7N9) are effective in disease control because they are protective and allow mass administration. Of note, these vaccines elicit undetectable H7N9-specific hemagglutination-inhibition (HI) but high IgG antibodies in chickens. However, the molecular basis and protective mechanism underlying this particular antibody immunity remain unclear. Herein, immunization with an NDVvecH7N9 induced low anti-H7N9 HI and virus neutralization titers but high levels of hemagglutinin (HA)-binding IgG antibodies in chickens. Three residues (S150, G151 and S152) in HA of H7N9 virus were identified as the dominant epitopes recognized by the NDVvecH7N9 immune serum. Passively transferred NDVvecH7N9 immune serum conferred complete protection against H7N9 virus infection in chickens. The NDVvecH7N9 immune serum can mediate a potent lysis of HA-expressing and H7N9 virus-infected cells and significantly suppress H7N9 virus infectivity. These activities of the serum were significantly impaired after heat-inactivation or treatment with complement inhibitor, suggesting the engagement of the complement system. Moreover, mutations in the 150-SGS-152 sites in HA resulted in significant reductions in cell lysis and virus neutralization mediated by the NDVvecH7N9 immune serum, indicating the requirement of antibody-antigen binding for complement activity. Therefore, antibodies induced by the NDVvecH7N9 can activate antibody-dependent complement-mediated lysis of H7N9 virus-infected cells and complement-mediated neutralization of H7N9 virus. Our findings unveiled a novel role of the complement in protection conferred by the NDVvecH7N9, highlighting a potential benefit of engaging the complement system in H7N9 vaccine design.

Superior Efficacy of Apathogenic Genotype I (V4) over Lentogenic Genotype II (LaSota) Live Vaccines against Newcastle Disease Virus Genotype VII.1.1 in Pathogen-Associated Molecular Pattern-H9N2 Vaccinated Broiler Chickens.

A comparison of the efficacy of apathogenic genotype I (V4) and lentogenic genotype II (LaSota) strains of live Newcastle disease virus (NDV) vaccines was performed following vaccination with pathogen-associated molecular pattern (PAMP) H9N2 avian influenza vaccine and challenge with velogenic NDV genotype VII.1.1 (vNDV-VII.1.1). Eight groups (Gs) of day-old chicks were used (n = 25). Groups 1-4 received a single dose of PAMP-H9N2 subcutaneously, while Gs (1, 5) and (2, 6) received eye drops of V4 and LaSota, respectively, as two doses. All Gs, except for 4 and 8, were intramuscularly challenged with vNDV-VII.1.1 at 28 days of age. No signs were detected in Gs 1, 5, 4, and 8. The mortality rates were 0% in Gs 1, 4, 5, and 8; 40% in G2; 46.66% in G6; and 100% in Gs 3 and 7. Lesions were recorded as minimal in Gs 1 and 5, but mild to moderate in Gs 2 and 6. The lowest significant viral shedding was detected in Gs 1, 2, and 5. In conclusion, two successive vaccinations of broilers with a live V4 NDV vaccine provided higher protection against vNDV-VII.1.1 challenge than LaSota. PAMP-H9N2 with live NDV vaccines induced more protection than the live vaccine alone.

The influence of Spirulina extract on pathogenicity, immune response, and vaccine efficacy against H9N2 avian influenza virus in specific pathogen free chickens

Avian influenza (AI) viruses pose a risk to the worldwide poultry industry. Ultimately, improving the efficiency of the H9N2 vaccine is necessary to better control low-pathogenic avian influenza-H9N2 by using natural immunostimulant. Therefore, the goal of the present study was to examine varying doses of the cyanobacterium Spirulina extract on the effectiveness of H9N2 vaccine. Thus, a total of 150 specific pathogen-free (SPF) chickens were allocated into 6 groups, 25 birds each, as follow: G1, G2, and G6 were supplemented with 200, 400, and 400 mg Spirulina extract/kg feed, respectively, whilst the feed in G3, G4, and G5 were not supplemented with Spirulina extract. At 21-days-old, only the chickens in G1, G2, and G3 were vaccinated with the H9N2 AI vaccine. After 4 wk postvaccination, the chickens in G1, G2, G3, G4, and G6 were challenged with H9N2 AI Egyptian strain. The challenged virus was selected from a recent circulating Egyptian strain during 2022, and it was related to A/quail/Hong Kong/G1/97-like virus lineage and clustered with G1-B sub-lineage EGY-2 group. It had a high amino acids identity percentage of 92.6% with the A/chicken/Iran/av1221/1998 (Boehringer Ingelheim) vaccine. The results of real-time reverse-transcriptase polymerase-chain-reaction (rRT-PCR) revealed that no shedding of the virus was reported in G1, G2, G3, and G5. The supplementation of Spirulina extract in low (200 mg/kg of feed) and high (400 mg/kg of feed) concentration with the birds vaccinated with H9N2 AI vaccine (G1 and G2) induced prominent immuno-stimulatory effect in a dose dependent manner where it strongly enhanced the phagocytic activities of broilers' peripheral blood monocytes, and lysozyme at all days postvaccination (dpv) and days postchallenge (dpc) compared to other groups with significant differences at all day of experiment and 21st dpv, 28th dpv, 7th dpc, and 14th dpc, respectively. The supplementation with Spirulina extract in G1 and G2 induced the highest hemagglutination inhibition antibody titer in a dose-dependent manner at all-time intervals. The antibody titer postvaccination was significantly increased in G1 and G2 at 14th, and 21st dpv, in comparison with G3. Furthermore, G1 and G2 showed higher significant antibody titers at 7th and 14th dpc, compared to other groups. Furthermore, Spirulina extract (200 and 400 mg/kg feed) in G1 and G2 showed anti-inflammatory effect in a dose dependant manner by downregulating nitric oxide levels at all times postchallenge with a significant difference at 3 to 7 dpc compared to G3, G4, and G6, with improved histopathological alterations in the trachea, lung, kidney, spleen, and bursa of Fabricius. G6 supplied with 400 mg/kg Spirulina extract feed only without vaccination had a similar effect as vaccinated groups on innate immunity. However, it delayed the production of antibodies and did not prevent viral shedding as in vaccinated groups. In conclusion, vaccination in conjunction with either dose of Spirulina extract (G1, and G2) prevents viral shedding, increases the immune response, and reduces inflammation and histopathological change caused by H9N2 AI infection in a dose dependent manner. We recommend the use of 400 mg Spirulina extract/kg feed as a natural immunostimulant in conjunction with the H9N2 vaccine to achieve the highest possible level of protection against H9N2 AI infection.

Effect of Echinacea purpurea (L.) Moench and its extracts on the immunization outcome of avian influenza vaccine in broilers

Ethnopharmacological relevanceEchinacea purpurea (L.) Moench (EP) is a perennial herbaceous flowering plant with immunomodulatory effects. However, the immunomodulatory effects of EP on broilers after vaccination are still unclear. Aim of the studyThe aim is to study the effect of EP and Echinacea purpurea (L.) Moench extracts(EE) on avian influenza virus (AIV) immunity, and further explore the potential mechanism of immune regulation. Materials and methodsBroilers were fed with feed additives containing 2% EP or 0.5% EE, and vaccinated against avian influenza. The samples were collected on the 7th, 21st, and 35th day after vaccination, and the feed conversion ratio (FCR) was calculated. Blood antibody titer, jejunal sIgA content, tight junction protein, gene and protein expression of TLR4-MAPK signaling pathway were also detected. ResultsThe results showed that vaccination could cause immune stress, weight loss, increase sIgA content, and up-regulate the expression of tight junction proteins, including zonula occludens-1 (ZO-1), Occludin, and Claudin-1, as well as the genes of Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), receptor-associated factor 6 (TRAF6), activator protein 1 (AP-1) protein gene expression on TLR4-mitogen-activated protein kinase (MAPK) signaling pathway, and the protein expression of MyD88, extracellular regulated protein kinases (ERK), and c-Jun N-terminal kinase (JNK). EP and EE could increase the body weight of broilers, further improve antibody titers, decrease FCR, increase sIgA levels, up-regulate the expression of tight junction proteins, including ZO-1, Occludin, and Claudin-1, as well as the genes of TLR4, MyD88, TRAF6, and AP-1 and the protein expression of MyD88, ERK, and JNK in the TLR4-MAPK signaling pathway. ConclusionIn conclusion, EP and EE can increase the broiler's production performance and improve vaccine immune effect through the TLR4-MAPK signaling pathway.

The First International Avian Influenza Summit. The University of Arkansas. October 16-17, 2023

Dear Esteemed Guests, Distinguished Speakers, Honorable Delegates, and all participants worldwide With great pleasure and excitement, we extend our warmest welcome to the First International Avian Influenza Summit, a momentous event hosted by the Center of Excellence in Poultry Science of the University of Arkansas. This groundbreaking summit, set to take place in Fayetteville, Arkansas, USA, on October 16-17, 2023, promises to be a significant milestone in the global efforts to combat Avian Influenza. Through the convergence of leading experts, innovators, and stakeholders worldwide, we aim to forge new frontiers in research, policy, and industry collaboration. The unique free hybrid format of this event, blending both in-person and virtual participation (a total of 1,842 participants from all over the world, see Figure 1), ensures that knowledge exchange and networking opportunities are accessible to a diverse and global audience. Whether you join us in Fayetteville or connect remotely, you will be crucial in advancing our collective understanding and response to this critical challenge. Over the course of two days, the summit will feature a dynamic program encompassing keynote addresses, panel discussions, workshops, and interactive sessions. Together, we will explore the latest advancements in avian influenza research, surveillance strategies, vaccination initiatives, and emergency response protocols. Moreover, this summit provides a vital platform for fostering collaborations between academia, industry, government agencies, and non-governmental organizations. By harnessing all stakeholders’ collective expertise and resources, we can catalyze innovation and drive solutions that protect both avian and human populations. In the spirit of unity and shared purpose, we look forward to the stimulating conversations, valuable insights, and lasting connections that will emerge from this summit. Together, we can profoundly impact the global fight against Avian Influenza. Once again, welcome to the First International Avian Influenza Summit. We are honored to have you with us, and we are confident that your contributions will help pave the way for a safer and more resilient future.

Vaccination against highly pathogenic avian influenza (HPAI): From opposition to acceptance. Proceeding of The First International Avian Influenza Summit, University of Arkansas- October 16-17, 2023”

The emergence of Highly Pathogenic Avian Influenza (HPAI) strains poses a significant threat to both avian populations and human health. Vaccination has been identified as a critical tool in mitigating the spread of HPAI. However, the acceptance and implementation of avian influenza vaccination programs have been met with opposition from various stakeholders, including poultry producers, public health authorities, and consumers. This abstract provides a comprehensive overview of the evolving landscape of HPAI vaccination strategies, tracing the trajectory from initial resistance to widespread acceptance. Initially, concerns surrounding vaccine efficacy, potential adverse effects, and the economic burden associated with large-scale vaccination campaigns led to hesitancy among poultry producers and industry stakeholders. Additionally, public health authorities grappled with challenges related to regulatory approval, vaccine strain selection, and the development of robust surveillance systems. Over time, advancements in vaccine technology and extensive research demonstrating the safety and effectiveness of HPAI vaccines have gradually shifted perceptions. Adopting innovative vaccination strategies, such as vector-based vaccines and recombinant technologies, has addressed previous limitations and bolstered confidence in immunization as a viable control measure. Moreover, collaborative efforts between international organizations, governments, and research institutions have played a pivotal role in establishing standardized vaccine development, distribution, and administration protocols. These endeavors have facilitated harmonizing global strategies and enhanced the preparedness and response mechanisms for potential HPAI outbreaks. Consumer attitudes have also evolved, driven by increased awareness of the public health implications of avian influenza and a growing demand for sustainable and ethically produced poultry products. This shift in consumer sentiment has incentivized industry stakeholders to embrace vaccination as a proactive measure to safeguard both avian welfare and human health. In conclusion, this abstract highlights the transformative journey of HPAI vaccination programs, underscoring the pivotal role of scientific innovation, collaborative partnerships, and evolving consumer perspectives in overcoming initial resistance. As the global community continues to confront emerging infectious diseases, the successful trajectory of HPAI vaccination provides valuable insights into the dynamic interplay between science, policy, and public perception in the face of evolving health challenges.

Evaluation the effect of dietary vitamin E, sesamin and thymoquinone bioactive compounds on immunological response, intestinal traits and MUC-2 gene expression in broiler Japanese quails (Coturnix japonica)

The current study was performed to determine the effect of dietary vitamin E, sesamin and thymoquinone bioactive lignans derived from sesame and black seed on immunological response, intestinal traits and Mucin2 gene expression in broiler quails. Three hundred and fifty (one days-old) quails were allotted to seven dietary treatments with five replicates as an experimental randomized design study. Treatments were basal diet as a control, control +100 and +200 mg of vitamin E, sesamin and thymoquinone per each kg of diet respectively. At 35 d of age, two quails from each pen were chosen, weighted, slaughtered, eviscerated and lymphoid organ relative weights were measured. Anti-body titers against Newcastle disease (ND), Sheep red blood cell (SRBC), and infectious bronchitis virus (IBV) and Avian influenza (AI) vaccination were determined. The serum activities of alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and serum antioxidant activates such as superoxide dismutase (SOD),glutathione peroxidase(GPX), catalase (CAT) and total antioxidant capacity (TAC) were examined. The cell mediated immunity by dinitrochlorobenzene (DNCB) and phytohemagglutinin (PHA) challenges were assessed. The microflora populations of ileum, morphological traits of jejunum and mucin2 gene expression were analyzed. Data showed that the lymphoid organ (thymus, spleen and Bursa) relative weights and antibody titer against HI, AI, SRBC and IB vaccination were increased compared to the control (p ≤ 0.05). Serum activities of ALP, ALT and AST were decreased under influences of dietary treatments (p ≤ 0.05). The serum antioxidant activates of GPX,SOD,CAT and TAC were increased and Increasing in mean skin thickness after DNCB challenge and decrease wing web swelling response to PHA mitojen injection were observed (p ≤ 0.05). Salmonella enterica, E-coli and Coliforms colonies were decrease and Lactobacillus colonies increased instead (p ≤ 0.05). The villus height and surface, crypt depth and goblet cells density were increased compared to the control (p ≤ 0.05). The expression of MUC2 gene increased under influnces of vitamin E, sesamin and thymoquinone supplemented diets (p ≤ 0.05).

Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses.

Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1.2, H5N8 clade 2.3.4.4b and the recent H5N1 clade 2.3.4.4b, have been reported among poultry populations in Egypt. This demanded the utilization of a nationwide routine vaccination program in the poultry sector. Antigenic differences between available avian influenza vaccines and the currently circulating H5Nx strains were reported, calling for an updated vaccine for homogenous strains. In this study, three H5Nx vaccines were generated by utilizing the reverse genetic system: rgH5N1_2.3.4.4, rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. Further, the immunogenicity and the cross-reactivity of the generated inactivated vaccines were assessed in the chicken model against a panel of homologous and heterologous H5Nx HPAIVs. Interestingly, the rgH5N1_2.3.4.4 induced high immunogenicity in specific-pathogen-free (SPF) chicken and could efficiently protect immunized chickens against challenge infection with HPAIV H5N1_2.3.4.4, H5N8_2.3.4.4 and H5N1_2.2.1.2. In parallel, the rgH5N1_2.2.1.2 could partially protect SPF chickens against infection with HPAIV H5N1_2.3.4.4 and H5N8_2.3.4.4. Conversely, the raised antibodies to rgH5N1_2.3.4.4 could provide full protection against HPAIV H5N1_2.3.4.4 and HPAIV H5N8_2.3.4.4, and partial protection (60%) against HPAIV H5N1_2.2.1.2. Compared to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2 vaccines, chickens vaccinated with rgH5N1_2.3.4.4 showed lower viral shedding following challenge infection with the predefined HPAIVs. These data emphasize the superior immunogenicity and cross-protective efficacy of the rgH5N1_2.3.4.4 in comparison to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2.

Lactobacillus plantarum GX17 benefits growth performance and improves functions of intestinal barrier/intestinal flora among yellow-feathered broilers.

Lactobacillus plantarum has recently been found to be a natural source feed additive bacteria with great advantages in food safety and animal welfare. Discovering novel strains with commercial application potentiation could benefit the local poultry industry, and in particular support Chinese farmers. In this study, we tested a recently isolated novel strain of Lactobacillus plantarum GX17 as a feed additive on the growth performance and intestinal barrier functions of 1-day-old Chinese yellow-feather chicks. As good as other commercial probiotics, feeding with Lactobacillus plantarum GX17 showed significant improvements in humoral immune responses and enhanced the immune effect after vaccination for either the Newcastle disease vaccine or the avian influenza vaccine. This study also found that feeding with Lactobacillus plantarum GX17 improved the feed-to-weight ratio and caused a significant increase of the villus length to crypt depth ratio. Furthermore, Lactobacillus plantarum GX17 significantly up-regulated the mRNA expression of CLDN, MUC2, and TLR2, all of which are jejunum-associated barrier genes, indicating an improvement of the intestinal barrier functions by enhancing the tight junction between epithelia cells. These results are comparable to the effects of feeding the commercial complex probiotics that improve the expression levels of CLDN, ocludin, MUC2, TLR2, and TLR4. In terms of maintaining intestinal health, commercial complex probiotics increased the relative abundance of Parabacteroides and Romboutsia, while Lactobacillus plantarum GX17 increased the relative abundance of Pseudoflavonifractor. Our data suggest that Lactobacillus plantarum GX17 could enhance the intestinal absorption of nutrients and therefore improve the growth performance of Chinese yellow-feather chicks. In conclusion, compared with the commercial complex probiotics, Lactobacillus plantarum GX17 has more positive effects on the growth performance and intestinal barrier function of yellow-feather chickens, and can be used as a feed additive.

Avian influenza vaccine supply chain in Quang Ninh province, Vietnam, 2021

Highly pathogenic avian influenza (HPAI) is a zoonotic disease that can affect both poultry and humans. Since 2005, the Vietnam government has implemented a national vaccination campaign to prevent the spread of avian influenza (AI). In 2021, the first outbreak of HPAI H5N8 was reported in a chicken farm in Quang Ninh province. To understand the stakeholders linked to the AI campaign, and their roles within the vaccine supply chain, we conducted a cross-sectional study from November 2021–January 2022. We purposively selected 114 participants, including 71 poultry farmers using HPAI vaccines, 16 veterinary drug store owners, 18 commune animal health workers (CAHWs), 8 staff from the Centers for Agricultural Services (ATSCs), and one vaccine distributor who were interviewed face-to-face using a structured questionnaire. Three HPAI vaccines (H5N1 clade 1 & 2.3.2.1, H5N1 clade 2.3.4 and H5N1 clade 2.3.2.1b) were used, and they were effective against the locally circulating virus strains. Distributors stored vaccines at the required temperature and transported them in appropriate vehicles. Vaccines remained in the supply chain for 3–5 months within their 12-month shelf-life period. The free government vaccination campaign, implemented by CAHWs, and administered by the ATSCs, reached 61% of small-scale poultry farms with a 1.21% vaccine wastage rate. Large-scale poultry farms followed the national campaign but paid a fee for the vaccines. We recommend expanding the support for AI vaccination to increase the vaccination rate among large-scale poultry farms, selecting higher efficacy seed vaccines, and that smaller dose vaccine vials are available for cost-effective vaccination.

Engineered Newcastle disease virus expressing the haemagglutinin protein of H9N2 confers protection against challenge infections in chickens

The Newcastle disease (ND) and avian influenza (AI) are two crucial viral ailments of poultry birds. In field conditions, these are controlled by vaccination and biosecurity measures. The cumbersome application process, potential for reversion to the wild pathogen, and financial load on farmers are only a few drawbacks of the currently available ND and AI vaccines. There was a pressing need to develop a stable, safer, bivalent vaccine for these two diseases. Hence, this study adopts the reverse genetic technology, thereby rescuing the recombinant LaSota strain of NDV, which expresses the haemagglutinin (HA) protein of indigenously isolated H9N2 virus (rNDV-H9). The rNDV-H9 was tested in terms of pathogenicity and growth kinetics. Subsequently, the day-old broiler chicks were immunised with rNDV-H9, followed by challenge infection by virulent NDV and H9N2 viruses. The results indicate that immunisation with rNDV-H9 has reduced the shedding of challenge viruses. The clinical progression of the diseases was slowed down, and all the birds were seroconverted. Results in this study indicate that rNDV-H9 is a promising candidate for immunisation in endemic areas of ND and AI, with minimum economic pressure on farmers and reduced vaccinal stress on poultry birds.

Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.

Worldwide, high pathogenic avian influenza viruses belonging to clades 2.3.4.4 and 2.3.2.1 have been circulating in both poultry and wild birds. Since 2018, Korea has built a national antigen bank to ensure preparedness in an emergency. In this study, we developed a bivalent vaccine candidate containing antigens derived from two reassortant KA435/2.3.2.1d and H35/2.3.4.4b strains for Korean national antigen bank. We evaluated its immunogenicity and protective efficacy in specific pathogen free chickens. The two vaccine strains, rgKA435-H9N2 PB2/2.3.2.1d and rgH35/2.3.4.4b, both of which were generated successfully by reverse genetics, were highly immunogenic (titres of haemagglutination inhibition: 8.3 and 8.4 log2, respectively) and showed good protective efficacy (100 and 147 50% protective dose, respectively) against lethal challenge with wild-type virus when delivered as a 1:1 mixture. Notably, the vaccine provided complete protection against viral shedding at a full dose (512 HAU) and a 1/10 dose (51.2 HAU), with no clinical signs, after challenge with H35/2.3.4.4b. The bivalent vaccine developed in this study may reduce the cost of vaccine production and could be used as a H5 subtype avian influenza vaccine candidate against two clades simultaneously.

Efficacy of Hemagglutinin Gene of Highly Pathogenic Avian Influenza as a Vaccine Candidate in Poultry: A Review

The most prevalent fatal disease in poultry that can result in high morbidity and mortality is highly pathogenic avian influenza (HPAI), subtype H5N1. A vaccination program is the most frequent way to prevent HPAI cases in poultry, especially against the H5 subtype of HPAI. There are currently a number of avian influenza vaccines available, including recombinant and inactivated whole virus vaccines. The foundation of a recombinant vaccine is possible by the expression of an avian influenza gene of interest following insertion into a carrier vector (no pathogenic virus). A recombinant HPAI vaccine is required to further challenge avian influenza cases in poultry. As a recombinant vaccine inserted into a carrier vector, the hemagglutinin (HA) gene has proven effective. The recombinant Herpes Virus Turkey (rHVT) vector vaccine for avian influenza has been discovered and is commercially available. The rHVT vaccine was developed using a hemagglutinin insert from the HPAI virus clade 2.2. Overall, studies in this review aimed to determine the efficacy of any developed recombinant avian influenza vaccine that uses the HA gene from different clades challenged with any avian influenza virus (AIV) isolate. It was found that the efficacy of hemagglutinin as a recombinant vaccine could be promising for future HPAI vaccine development. In addition, it is possible to design a recombinant vaccine using local isolates to protect poultry farms, particularly in endemic regions.

Recombinant hemagglutinin protein and DNA-RNA-combined nucleic acid vaccines harbored by yeast elicit protective immunity against H9N2 avian influenza infection

A safe, convenience, and effective vaccine for controlling avian influenza virus infection is crucial in scale poultry production. Yeasts are considered useful vaccine vehicles for the delivery of antigens, which has been used to protect human and animal health. We report here the development of H9N2 strain hemagglutinin (HA)-based recombinant protein vaccines (rH9HA) and DNA-RNA-combined vaccine (rH9-DNA-RNA) in Saccharomyces cerevisiae for the first time. The immunogenicity assay indicated that both rH9HA and rH9-DNA-RNA could induce robust production of serum IgG, mucosal sIgA, and cellular immune responses. The reshape and diversification of gut microbiota and an enriched Lactobacillus, Debaryomyces were observed after oral immunization with rH9HA or rH9-DNA-RNA yeast vaccine, which might contribute to modulate the intestinal mucosal immunity and antiviral process. Oral immunized birds with either rH9HA or rH9-DNA-RNA were effectively protected from H9N2 virus challenge. Our findings suggested that yeast-derived H9N2 HA-based recombinant protein vaccines and DNA-RNA-combined nucleic acid vaccines are feasible and efficacious, opening up a new avenue for rapid and cost-effective production of avian influenza vaccines to achieve good protection effect.

Cationic Nanoparticle-Stabilized Vaccine Delivery System for the H9N2 Vaccine to Promote Immune Response in Chickens.

Chinese yam polysaccharides (CYPs) have received wide attention for their immunomodulatory activity. Our previous studies had discovered that the Chinese yam polysaccharide PLGA-stabilized Pickering emulsion (CYP-PPAS) can serve as an efficient adjuvant to trigger powerful humoral and cellular immunity. Recently, positively charged nano-adjuvants are easily taken up by antigen-presenting cells, potentially resulting in lysosomal escape, the promotion of antigen cross-presentation, and the induction of CD8 T-cell response. However, reports on the practical application of cationic Pickering emulsions as adjuvants are very limited. Considering the economic damage and public-health risks caused by the H9N2 influenza virus, it is urgent to develop an effective adjuvant for boosting humoral and cellular immunity against influenza virus infection. Here, we applied polyethyleneimine-modified Chinese yam polysaccharide PLGA nanoparticles as particle stabilizers and squalene as the oil core to fabricate a positively charged nanoparticle-stabilized Pickering emulsion adjuvant system (PEI-CYP-PPAS). The cationic Pickering emulsion of PEI-CYP-PPAS was utilized as an adjuvant for the H9N2 Avian influenza vaccine, and the adjuvant activity was compared with the Pickering emulsion of CYP-PPAS and the commercial adjuvant (aluminum adjuvant). The PEI-CYP-PPAS, with a size of about 1164.66 nm and a ζ potential of 33.23 mV, could increase the H9N2 antigen loading efficiency by 83.99%. After vaccination with Pickering emulsions based on H9N2 vaccines, PEI-CYP-PPAS generated higher HI titers and stronger IgG antibodies than CYP-PPAS and Alum and increased the immune organ index of the spleen and bursa of Fabricius without immune organ injury. Moreover, treatment with PEI-CYP-PPAS/H9N2 induced CD4+ and CD8+ T-cell activation, a high lymphocyte proliferation index, and increased cytokine expression of IL-4, IL-6, and IFN-γ. Thus, compared with the CYP-PPAS and aluminum adjuvant, the cationic nanoparticle-stabilized vaccine delivery system of PEI-CYP-PPAS was an effective adjuvant for H9N2 vaccination to elicit powerful humoral and cellular immune responses.

Evaluation of inactivated vaccine's Antibody response to different H9N2 Vaccination programs with Hemagglutination Inhibition (HI) assay

Influenza is a significant poultry disease that can also affect humans, making it a zoonosis. The World Health Organization (WHO) and Contagious Diseases Organization (CDO) have increasingly focused on this disease in recent years. The isolation of influenza, particularly H5N1 and H9N2 subtypes, has dramatically increased, posing a global epidemic threat and causing deaths in various communities, as well as substantial losses in poultry. In response, using inactivated avian influenza vaccines has become common in controlling the disease. A comprehensive study was conducted in broiler farms in Iran to address the importance of influenza control through vaccination. The study involved 50,000 broiler chicks divided into seven groups with different vaccination programs. The groups were vaccinated at different ages and received varying vaccine doses. Serum samples were collected weekly and analyzed for antibody titers using hemagglutination inhibition (HI). The results showed that the groups vaccinated after seven days of age had a more consistent immune response and higher antibody titers than those vaccinated at a younger age or with only one dose. Early vaccination before seven days of age did not effectively stimulate the desired antibody response or achieve expected titers for the H9N2 influenza virus. Therefore, vaccinating older chicks improved immunity and flock protection more effectively. This study highlights the importance of vaccination strategies in controlling influenza in broiler farms. It provides valuable insights into the optimal timing and dosage of vaccines to enhance the immune response and protect against the H9N2 subtype. Implementing appropriate vaccination programs can contribute to mitigating the impact of influenza on poultry and reducing the risk of transmission to humans, ultimately safeguarding both animal and public health.

Post-Vaccination AI (Avian Influenza) Antibody Levels in Superior Native Chicken Balitnak (Kub Chicken) with Arab Chicken Aged 25 Days

In Indonesia, native chickens are still in demand by the community. However, this type of chicken has low productivity compared to purebred chickens. At this time, there has been a type of native chicken that is Arab Chicken that has been widely developed in Indonesia because it has better endurance than other native chickens. In addition to Arabic chickens, there are also KUB chickens developed by the Bogor Livestock Research Institute to address the problem of low productivity of native chickens. But these two types of chickens remain susceptible to diseases, such as Avian Influenza (AI). To overcome this breeders conduct AI vaccinations using inactive vaccines. This study aims to find out the difference between post-vaccination antibodies between KUB chickens and Arab chickens. This research has been conducted from June to August 2018. The chickens used amounted to 40 chickens (20 KUB chickens and 20 Arab chickens). The chickens are kept from the age of one day and placed in two separate cages according to their breed. Intracardial blood sampling was pre-treatment (three days old) for the 40 chickens. At the age of four days, the chickens were injected with an inactive AI vaccine, and 21 days later blood sampling was again carried out (post-treatment). HI, tests are used to find out titer antibodies pre and post-treatment. The results of antibody titer readings were then analyzed using a t-test and Geometric Mean Titer test (GMT). T-test results showed that T value (6,364)>T table (1,734), so the results of this study showed that the titer antibodies formed are different (P<0.05). KUB chickens have higher antibody titers than Arab chickens.

Influence of Sodium Butyrate on Provoke of Immune Response in Vaccinated Broilers With Avian Influenza (H9N2) Vaccines

Influence of Sodium Butyrate on Provoke of Immune Response in Vaccinated Broilers With Avian Influenza (H9N2) Vaccines

Live recombinant Newcastle disease virus vectored vaccine expressing the haemagglutinin of H9N2 avian influenza virus suppresses viral replication in chickens

ABSTRACT In 2020, the Y280-lineage H9N2 low-pathogenic avian influenza virus (LPAIV) was introduced into South Korea for the first time. Current vaccines are focused on the control of Y439-like viruses; however, there are continuous reports of decrease in egg production and secondary infections caused by Y280-lineage H9N2 LPAI infection in chickens. Therefore, there is an urgent need to develop effective novel vaccines against Y280-lineage H9N2 LPAI. Most commercialized avian influenza vaccines are oil-adjuvanted inactivated vaccines, which are labour-intensive to administer and require higher dosage. In this study, rK148/Y280-HA, a novel recombinant Newcastle disease virus (NDV) vectored vaccine against Y280-lineage H9N2 LPAI, was developed and evaluated using two mass-applicable administration methods, spray vaccination and drinking water vaccination. Regardless of low serum antibody haemagglutination inhibition titres against NDV and Y280-lineage H9N2 LPAI after applying the rK148/Y280-HA vaccine, vaccination with either administration method protected chickens against virulent NDV and Y280-lineage H9N2 LPAIV after the challenge. Taken together, these results indicate that the rK148/Y280 vaccine can be administered using facile mass-application methods to provide protection against the Y280-lineage LPAI. RESEARCH HIGHLIGHTS NDV vectored vaccine harbouring Y280-lineage H9N2 HA protein was successfully generated. NDV vectored vaccine provides protection against NDV. NDV vectored vaccine with H9N2 HA protects against homologous H9N2 LPAIV.

Reverse genetics based H5N2 vaccine provides clinical protection against H5N1, H5N8 and H9N2 avian influenza infection in chickens

The current study aimed to develop broadly protective vaccines for avian influenza. In an earlier study, HA stalk (universal flu vaccine) was found to be broadly protective against different subtypes of influenza virus in mice. Hence, we were interested to know its breadth of protective efficacy either alone or combined with inactivated rgH5N2 (clade 2.3.2.1a) vaccine against challenge viruses of homologous H5N1, heterologous H5N8 (clade 2.3.4.4) and heterosubtypic H9N2 virus in specific pathogen-free chickens. The rgH5N2 vaccine alone or in combination with HA stalk elicited sufficient pre-challenge immunity in the form of haemagglutination inhibiting (HI) antibodies and neutralizing antibodies (MNT) against H5N1, H5N8, and H9N2 in chickens. The rgH5N2 vaccine alone or in combination with HA stalk also attenuated the shedding of H5N1, H5N8 and H9N2 in chickens and protected against the lethal challenge of H5N1 or H5N8. In contrast, all HA stalk immunised chickens died upon H5N1 or H5N8 challenge and H9N2 challenged chickens survived. Our study suggests that the rgH5N2 vaccine can provide clinical protection against H5N1, H5N8 and can attenuate the viral shedding of H9N2 in chickens.